2216 — Broncus Holding Share Price
0.000.00%
Last trade - 00:00- HK$553.43m
- -HK$423.05m
- $0.17m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.47 | ||
| Price to Tang. Book | 0.49 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 406.07 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -11.9% | ||
| Return on Equity | -11.19% | ||
| Operating Margin | -10270.11% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 10.89 | 9.41 | 10.26 | 8.13 | 0.17 | 16.85 | 21.73 | -44.35% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Broncus Holding Corp is an investment holding company primarily engaged in the research and development, and the manufacture and commercialisation of medical devices and consumables. The Company’s lung cancer treatment pipeline products primarily include the BroncAblate radiofrequency ablation system, a transbronchial interventional treatment product. The chronic obstructive pulmonary disease (COPD) treatment pipeline products primarily include the InterVapor thermal vapor treatment system and the lung targeted denervation (TLD) radiofrequency ablation energy system. The other lung disease diagnostic and treatment pipeline products primarily include the Mist Fountain disposable nebulizing micro-catheter for endoscope and the BroncTru disposable transbronchoscopic dilatation catheter. The other products primarily include navigation-based flexible surgical robot and the lung image processing software BroncQCT. The Company operates its businesses in the domestic and overseas markets.
Directors
- Yiwei Zhao NEC (55)
- Guowei Zhan CEO (45)
- Todd Cornell CEX (51)
- Hong Xu CTO (35)
- Zhenhua Li DSL (37)
- Jeanie Lau SEC (44)
- Wen Hao Wang SEC (48)
- Ao Zhang NED (36)
- Zhenjun Zi NED (51)
- Jian Ji NID (51)
- Pok Man Kam NID (71)
- Wan Yee Lau NID (74)
- Last Annual
- December 31st, 2025
- Last Interim
- December 31st, 2025
- Incorporated
- April 30th, 2012
- Public Since
- September 24th, 2021
- No. of Employees
- 191
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 527,079,084
- Address
- Room 801, 8/F, Building 8, HANGZHOU
- Web
- https://www.broncus.com/
- Phone
- Auditors
- Ernst & Young Australia
Upcoming Events for 2216
Broncus Holding Corp Annual Shareholders Meeting
Similar to 2216
Acotec Scientific Holdings
Stock Exchange of Hong Kong Limited
Beijing Airdoc Technology Co
Stock Exchange of Hong Kong Limited
AK Medical Holdings
Stock Exchange of Hong Kong Limited
AMCO United Holding
Stock Exchange of Hong Kong Limited
Angelalign Technology
Stock Exchange of Hong Kong Limited
FAQ
What is the Broncus Holding share price?
As of Today at 19:43 UTC, shares in Broncus Holding are trading at HK$1.05. This share price information is delayed by 15 minutes.
How has the Broncus Holding share price performed this year?
Shares in Broncus Holding last closed at HK$1.05 and the price had moved by -53.54% over the past 365 days. In terms of relative price strength the Broncus Holding share price has underperformed the FTSE Developed Asia Pacific Index by -74.01% over the past year.
What are the analyst and broker recommendations for Broncus Holding?
The overall consensus recommendation for Broncus Holding is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Broncus Holding dividend yield?
Broncus Holding does not currently pay a dividend.
Does Broncus Holding pay a dividend?
Broncus Holding does not currently pay a dividend.
When does Broncus Holding next pay dividends?
Broncus Holding does not currently pay a dividend.
How do I buy Broncus Holding shares?
To buy shares in Broncus Holding you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Broncus Holding?
As of the previous close price of HK$1.05, shares in Broncus Holding had a market capitalisation of HK$553.43m.
Where are Broncus Holding shares listed?
Here are the trading details for Broncus Holding:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 2216
What kind of share is Broncus Holding?
Based on an overall assessment of its quality, value and momentum Broncus Holding is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Broncus Holding share price forecast for 2026?
The analyst consensus target price for shares in Broncus Holding is HK$1.57. That is 49.29% above the last closing price of HK$1.05.
Analysts covering Broncus Holding currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreWhat is the trend in the Broncus Holding share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Broncus Holding. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -70.61%.
As of the last closing price of HK$1.05, shares in Broncus Holding were trading -54.56% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Broncus Holding PE Ratio?
The Broncus Holding PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$1.05.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Broncus Holding?
Broncus Holding's management team is headed by:
- Yiwei Zhao - NEC
- Guowei Zhan - CEO
- Todd Cornell - CEX
- Hong Xu - CTO
- Zhenhua Li - DSL
- Jeanie Lau - SEC
- Wen Hao Wang - SEC
- Ao Zhang - NED
- Zhenjun Zi - NED
- Jian Ji - NID
- Pok Man Kam - NID
- Wan Yee Lau - NID